COVID‐19‐related neuropathology and microglial activation in elderly with and without dementia

Abstract

The actual role of SARS-CoV-2 in brain damage remains controversial due to lack of matched controls. We aim to highlight to what extent is neuropathology determined by SARS-CoV-2 or by pre-existing conditions. Findings of 9Coronavirus disease 2019 (COVID-19) cases and 6 matched non-COVID controls (mean age 79 y/o) were compared. Brains were analyzed through immunohistochemistry to detect SARS-CoV-2, lymphocytes, astrocytes, endothelium, and microglia. A semi-quantitative scoring was applied to grade microglial activation. Thal-Braak stages and the presence of small vessel disease were determined in all cases. COVID-19 cases had a relatively short clinical course (0-32 days; mean: 10 days), and did not undergo mechanical ventilation. Five patients with neurocognitive disorder had delirium. All COVID-19 cases showed non-SARS-CoV-2-specific changes including hypoxic-agonal alterations, and a variable degree of neurodegeneration and/or pre-existent SVD. The neuroinflammatory picture was dominated by ameboid CD68 positive microglia, while only scant lymphocytic presence and very few traces of SARS-CoV-2 were detected. Microglial activation in the brainstem was significantly greater in COVID-19 cases (p = 0.046). Instead, microglial hyperactivation in the frontal cortex and hippocampus was clearly associated to AD pathology (p = 0.001), regardless of the SARS-CoV-2 infection. In COVID-19 cases complicated by delirium (all with neurocognitive disorders), there was a significant enhancement of microglia in the hippocampus (p = 0.048). Although higher in cases with both Alzheimer's pathology and COVID-19, cortical neuroinflammation is not related to COVID-19 per se but mostly to pre-existing neurodegeneration. COVID-19 brains seem to manifest a boosting of innate immunity with microglial reinforcement, and adaptive immunity suppression with low number How to cite this article:

Cerebrospinal Fluid Analysis Post–COVID‐19 Is Not Suggestive of Persistent Central Nervous System Infection

“…The current evidence for direct viral brain invasion in COVID‐19 is conflicting; the frequent detection of SARS‐CoV‐2 in brain reported by one group 5 was not confirmed by others. 18 , 19 These autopsy studies included older individuals that deceased from COVID‐19, demographics that substantially differed from our post–COVID‐19 patients. The same is true for published CSF studies assessing only the acute or ongoing phases of COVID‐19, 20 and lacking systematic antibody analyses.…”

Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson’s Disease?

“…Another group similarly found SARS-CoV-2 to favor CNS endothelial cells with the ACE-2-receptor expressed in smooth muscle cells of blood vessels [ 38 ]. Small vessel disease was identified in five out of nine COVID-19 autopsy cases; however, SARS-CoV-2 was only detected in one case using immunohistochemistry [ 39 ]. Detection of SARS-CoV-2 in the brain using PCR was equally difficult; the highest viral load was documented in the olfactory bulb, while SARS-CoV-2 PCR was repeatedly negative in the substantia nigra [ 30 , 34 , 40 ].…”

“…The brains of COVID-19 autopsy cases showed microglial activation in the olfactory bulb, frontal cortex, hippocampus and most prominently in the brainstem, whereas lymphocytes did not appear to be activated [ 39 ]. Interestingly, patients with a history of delirium during COVID-19 demonstrated more microglial activation in the hippocampus [ 39 ].…”

“…The brains of COVID-19 autopsy cases showed microglial activation in the olfactory bulb, frontal cortex, hippocampus and most prominently in the brainstem, whereas lymphocytes did not appear to be activated [ 39 ]. Interestingly, patients with a history of delirium during COVID-19 demonstrated more microglial activation in the hippocampus [ 39 ]. Patients with and without sepsis could not be distinguished neuropathologically, contradicting the common hypothesis that neuropathology develops secondary to a cytokine storm during septic disease [ 39 ].…”

A2A Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer’s Disease

“…Ng is a postsynaptic protein, which is increased in the CSF of patients with AD and is supposed to predict the decline in memory and executive function during the early stage of the disease [ 29 ]. Regarding inflammation and its important role in AD pathogenesis and its clinical worsening [ 30 , 31 , 32 ], it should be considered that there are no inflammatory markers in body fluids currently recognized as diagnostic for AD. Reports suggest a possible role of CSF proinflammatory cytokines levels, such as TNF-α, IL-1β or IL-6, as biomarkers of conversion of MCI to AD [ 33 ].…”